000143862 001__ 143862
000143862 005__ 20240229112610.0
000143862 0247_ $$2doi$$a10.1186/s12885-019-5710-5
000143862 0247_ $$2pmid$$apmid:31146706
000143862 0247_ $$2altmetric$$aaltmetric:61335764
000143862 037__ $$aDKFZ-2019-01424
000143862 041__ $$aeng
000143862 082__ $$a610
000143862 1001_ $$0P:(DE-He78)53e1a2846c69064e27790dbf349ccaec$$aHolleczek, Bernd$$b0$$eFirst author$$udkfz
000143862 245__ $$aRisk of loco-regional recurrence and distant metastases of patients with invasive breast cancer up to ten years after diagnosis - results from a registry-based study from Germany.
000143862 260__ $$aHeidelberg$$bSpringer$$c2019
000143862 3367_ $$2DRIVER$$aarticle
000143862 3367_ $$2DataCite$$aOutput Types/Journal article
000143862 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1561444537_7649
000143862 3367_ $$2BibTeX$$aARTICLE
000143862 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143862 3367_ $$00$$2EndNote$$aJournal Article
000143862 520__ $$aPopulation-based estimates of the long-term risk of loco-regional recurrence and distant metastases of breast cancer (BRC) patients are scant, as most published studies used hospital-based cohorts or participants of clinical trials. This work aims to extend available knowledge by providing population-based long-term estimates of the cumulative risk of BRC recurrence up to 10 years after diagnosis.Data from the population-based Saarland Cancer Registry were used and included 9359 female patients with primary invasive BRC diagnosed between 1999 and 2009. Estimates of the cumulative incidence (CI) of BRC recurrence were derived for patients who had received local surgery with free resection margins by type of recurrence and stratified by age, tumor characteristics and major treatment options, taking into account mortality from any cause as a competing risk.The 10-year CI of BRC recurrence was 16%. For loco-regional recurrence and distant metastases alone it was 8 and 11%, respectively. The estimates showed substantial variation and were particularly increased if tumors were advanced (T1/2N+ 23%, T3/4N0 24%, T3/4N+ 34%), of high grade (23%), or of 'HER2/neu positive' (28%) or 'triple negative' subtype (23%), respectively.The derived estimates reflect the risk of 'real world' patients and may therefore extend available knowledge. These data are thus of great relevance for clinicians, their patients and researchers. The study likewise demonstrated the usefulness of cancer registries for a population-based monitoring of the effectiveness of cancer care in terms of disease recurrence as a major treatment related outcome measure.
000143862 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000143862 588__ $$aDataset connected to CrossRef, PubMed,
000143862 7001_ $$aStegmaier, Christa$$b1
000143862 7001_ $$aRadosa, Julia C$$b2
000143862 7001_ $$aSolomayer, Erich-Franz$$b3
000143862 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b4$$eLast author$$udkfz
000143862 773__ $$0PERI:(DE-600)2041352-X$$a10.1186/s12885-019-5710-5$$gVol. 19, no. 1, p. 520$$n1$$p520$$tBMC cancer$$v19$$x1471-2407$$y2019
000143862 909CO $$ooai:inrepo02.dkfz.de:143862$$pVDB
000143862 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)53e1a2846c69064e27790dbf349ccaec$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000143862 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000143862 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000143862 9141_ $$y2019
000143862 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBMC CANCER : 2017
000143862 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143862 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143862 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000143862 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000143862 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000143862 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000143862 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review
000143862 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000143862 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000143862 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000143862 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143862 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143862 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143862 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000143862 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000143862 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lKlinische Epidemiologie und Alternsforschung$$x0
000143862 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000143862 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000143862 980__ $$ajournal
000143862 980__ $$aVDB
000143862 980__ $$aI:(DE-He78)C070-20160331
000143862 980__ $$aI:(DE-He78)C120-20160331
000143862 980__ $$aI:(DE-He78)L101-20160331
000143862 980__ $$aUNRESTRICTED